Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $970.39 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $372.99 | 3 | $0 (2024) |
| GlaxoSmithKline, LLC. | $248.40 | 2 | $0 (2023) |
| Lilly USA, LLC | $224.22 | 2 | $0 (2022) |
| ABBVIE INC. | $124.78 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $372.99 | 3 | AstraZeneca Pharmaceuticals LP ($372.99) |
| 2023 | $248.28 | 2 | ABBVIE INC. ($124.78) |
| 2022 | $224.22 | 2 | Lilly USA, LLC ($224.22) |
| 2021 | $124.90 | 1 | GlaxoSmithKline, LLC. ($124.90) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $120.39 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $130.76 | General |
| Category: Respiratory | ||||||
| 02/08/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Respiratory | ||||||
| 10/26/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $124.78 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $123.50 | General |
| 10/19/2022 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | Cash or cash equivalent | $119.92 | General |
| Category: Neuroscience | ||||||
| 08/04/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $104.30 | General |
| Category: Diabetes | ||||||
| 03/23/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $124.90 | General |
| Category: RESPIRATORY | ||||||
About Carl Smith
Carl Smith is a Addiction (Substance Use Disorder) healthcare provider based in Stanton, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1255547964.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Carl Smith has received a total of $970.39 in payments from pharmaceutical and medical device companies, with $372.99 received in 2024. These payments were reported across 8 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($970.39).
Practice Information
- Specialty Addiction (Substance Use Disorder)
- Location Stanton, CA
- Active Since 05/16/2007
- Last Updated 07/08/2007
- Taxonomy Code 101YA0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255547964
Products in Payments
- AIRSUPRA (Drug) $252.60
- TRELEGY ELLIPTA (Drug) $124.90
- QULIPTA (Drug) $124.78
- FARXIGA (Drug) $120.39
- EMGALITY (Drug) $119.92
- MOUNJARO (Drug) $104.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Addiction (Substance Use Disorder) Doctors in Stanton
Angela Wilson
Addiction (Substance Use Disorder)
Judy Rivas
Addiction (Substance Use Disorder)
Dennis Runner
Addiction (Substance Use Disorder)
Rosemarie Charifa, Lvn, LVN
Addiction (Substance Use Disorder)
Elaine De Mayo
Addiction (Substance Use Disorder)
Christine Picado
Addiction (Substance Use Disorder)